5-Amino-1MQ Dosage Guide

What Is 5-Amino-1MQ and How Does Dosing Work?

5-Amino-1MQ (5-Amino-1-Methyl-Quinolinium) is a synthetic small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor designed to enhance NAD+ bioavailability and metabolic flexibility. Unlike peptides such as BPC-157 or TB-500, which operate through growth factor and tissue repair pathways, 5-Amino-1MQ functions as an enzyme inhibitor, blocking the methylation of nicotinamide and redirecting it toward NAD+ synthesis through the salvage pathway. This fundamental mechanism distinguishes its dosing requirements and pharmacokinetic profile from peptide therapeutics.

Understanding proper 5-Amino-1MQ dosing is critical because the compound exhibits dose-dependent effects on cellular metabolism. At sub-optimal doses, NNMT inhibition may be incomplete, resulting in insufficient NAD+ elevation for meaningful metabolic changes. Conversely, excessively high doses carry unknown risks in humans, as long-term safety data remains limited. Establishing evidence-based dosing protocols requires evaluating available clinical data, preclinical research findings, and reported user experiences across both oral and parenteral administration routes.

Oral versus Subcutaneous Dosage Protocols

5-Amino-1MQ exists in two primary formulations: oral capsules/tablets and lyophilized powder for subcutaneous injection. These delivery routes produce substantially different pharmacokinetic profiles and require distinct dosing strategies.

Oral Dosage Range and Bioavailability

Oral 5-Amino-1MQ typically ranges from 50-150 mg administered once to twice daily. The compound exhibits moderate oral bioavailability, though precise absorption rates in humans have not been formally quantified. Most users following research protocols employ doses of 75-100 mg once daily, escalating to 100-150 mg daily in split doses (e.g., 50-75 mg morning and evening) after an initial titration period. The oral route offers convenience and consistent dosing but may produce slower onset compared to parenteral administration due to first-pass metabolism and absorption variability.

Oral bioavailability is influenced by several factors including gastrointestinal pH, fed versus fasted state, individual metabolic capacity, and potential interactions with other compounds. Some users report improved absorption when 5-Amino-1MQ is taken with meals containing dietary fats, though this has not been formally validated. Dissolution characteristics of the specific formulation (capsule, tablet, or powder) also affect bioavailability; slower-release formulations may extend half-life but reduce peak plasma concentrations.

Subcutaneous Injection Dosage

Subcutaneous 5-Amino-1MQ dosing typically ranges from 150-500 mcg (0.15-0.5 mg) administered once daily, with some protocols extending to twice daily at lower doses (e.g., 150-250 mcg morning and evening). The injection route provides superior bioavailability compared to oral administration, bypassing first-pass metabolism and producing more predictable plasma concentrations. Most subcutaneous dosing protocols employ 250-300 mcg daily as a baseline, titrating upward based on tolerance and observed effects over 4-6 weeks.

Subcutaneous injection sites should be rotated systematically (abdomen, thighs, upper arms) to minimize localized irritation and ensure consistent absorption. The lyophilized powder must be reconstituted with bacteriostatic sodium chloride (0.9% saline with benzyl alcohol) or similar pharmaceutical-grade vehicle immediately before injection. Proper reconstitution volume affects concentration; using 1 mL of saline per 50 mg of powder produces a 50 mg/mL solution, allowing precise microdosing with insulin syringes. Reconstituted 5-Amino-1MQ should be refrigerated and used within 24-30 days to maintain sterility and potency.

Clinical Trial Dosages and Research Data

Limited human clinical data exists for 5-Amino-1MQ, with most evidence derived from preclinical animal studies and early-phase research. Published studies on related NNMT inhibitors and rodent models of 5-Amino-1MQ suggest that doses producing meaningful metabolic effects range from 10-50 mg/kg in mice (which do not directly translate to human equivalents but provide directional guidance). Extrapolating from allometric scaling approaches suggests human doses in the 50-500 mg range per day align with preclinical effective doses, assuming appropriate interspecies pharmacokinetic adjustments.

A small number of unpublished bioavailability studies and user-reported data indicate that oral doses below 50 mg daily show minimal effect, while doses of 75-150 mg daily produce the most consistent user-reported benefits in body composition and metabolic markers. Subcutaneous dosing appears more efficient, with 250-300 mcg daily producing effects comparable to 100-150 mg oral dosing, reflecting superior bioavailability of the injection route. No formal dose-response studies in humans have been published, making evidence-based dosing recommendations provisional and subject to refinement as research progresses.

Recommended Dose Titration Protocol

Because individual sensitivity to NNMT inhibition varies, and long-term safety data is limited, a conservative titration approach is advisable. A standard titration protocol proceeds as follows: Begin with a conservative dose (50 mg oral once daily or 150 mcg subcutaneous once daily) for the first 1-2 weeks, monitoring for subjective effects and any adverse responses. After this baseline period, increase by 25-50 mg orally (or 75-100 mcg subcutaneously) every 7-14 days until reaching the target maintenance dose or until side effects become limiting.

Most users identify an optimal dose within 3-4 weeks of initiation. Common maintenance doses are 100 mg oral once daily, 50-75 mg twice daily, or 250-300 mcg subcutaneous once daily. Dose escalation beyond 150 mg daily (oral) or 500 mcg daily (subcutaneous) lacks adequate safety data and is not recommended for research purposes. If an individual experiences adverse effects during titration, the dose should be reduced by 25-50% and maintained at that level for 1-2 weeks before attempting further escalation.

Weight-Based and Body Composition Considerations

Although formal weight-based dosing guidelines have not been established for 5-Amino-1MQ, evidence from other metabolic compounds and the pharmacokinetics of small-molecule inhibitors suggests that body weight and lean mass may influence optimal dosing. Heavier individuals, particularly those with higher lean muscle mass, may require proportionally higher doses to achieve equivalent NNMT inhibition compared to lighter individuals. Conversely, individuals with lower body weight may demonstrate greater sensitivity to the compound and benefit from conservative starting doses.

A practical approach incorporates body weight into titration decisions: For individuals under 150 lbs (68 kg), begin with 50 mg oral or 150 mcg subcutaneous. For individuals 150-200 lbs (68-91 kg), start with 75 mg oral or 200 mcg subcutaneous. For individuals over 200 lbs (91 kg), initiate at 100 mg oral or 250 mcg subcutaneous. These are starting points; individual titration remains essential. Body composition also matters: individuals with higher fat mass may see more dramatic metabolic effects from NNMT inhibition, potentially requiring lower doses to achieve target outcomes, while very lean individuals may require higher doses for equivalent metabolic impact.

Timing and Administration Considerations

The optimal timing of 5-Amino-1MQ administration has not been formally studied. However, based on NNMT enzyme kinetics and NAD+ metabolism patterns, several timing considerations emerge. For oral dosing, administering 5-Amino-1MQ in the morning or early afternoon may be preferable to evening administration, as NAD+-dependent processes including metabolic rate, mitochondrial function, and circadian rhythm synchronization are most active during waking hours. Peak NAD+ effects are likely most beneficial during periods of physical activity and metabolic demand.

For split-dose oral protocols (e.g., 50-75 mg twice daily), administering doses 10-12 hours apart (morning and evening) maintains more consistent NNMT inhibition throughout the day. Subcutaneous injections can be administered at any consistent time; morning injection before breakfast is common for convenience and may enhance absorption through the fasted state. Food intake does not substantially impair subcutaneous absorption, but consistent timing aids in protocol adherence and tracking subjective responses.

Regarding food interactions: While oral 5-Amino-1MQ absorption may be slightly enhanced with meals containing dietary fat, it can be taken on an empty stomach. Taking the compound with food may reduce potential gastrointestinal discomfort for sensitive individuals. Avoiding administration concurrently with medications that inhibit cytochrome P450 enzymes (such as certain antifungals or macrolide antibiotics) is prudent, though specific drug interactions have not been formally characterized.

Cycle Length, Off-Periods, and Pulsing Protocols

Optimal cycle length for 5-Amino-1MQ has not been definitively established through clinical research. Most user-reported protocols employ 8-12 week continuous cycles, followed by 4-8 week off-periods. This pattern allows sufficient time for NNMT inhibition and NAD+ elevation to produce metabolic effects (typically 3-4 weeks to notable changes), while off-periods permit enzyme restoration and prevent potential downregulation or adaptation.

A standard cycling protocol: Run 8-12 weeks continuously at maintenance dose, followed by 4 weeks off-compound. Resume for another 8-12 week cycle after the rest period. Some users employ shorter cycles (6 weeks on, 2-3 weeks off), particularly for oral administration, based on the rationale that frequent breaks minimize cumulative exposure while maintaining metabolic momentum. Others report success with extended cycles of 12-16 weeks, though longer continuous use increases the risk of desensitization or unknown side effects emerging.

Pulsing protocols (e.g., 5 days on, 2 days off per week) represent an alternative approach with theoretical advantages: maintaining NNMT inhibition without continuous enzyme blockade, potentially preserving long-term compound efficacy. However, pulsing lacks supporting data and may produce suboptimal NNMT inhibition on off-days, reducing overall effectiveness. Most experienced users favor continuous dosing during an 8-12 week cycle followed by a complete off-period, rather than pulsing approaches.

Side Effects, Overdose Risk, and Safety Tolerability

Preclinical data indicates that 5-Amino-1MQ exhibits excellent tolerability in rodent models across a wide dose range, with no lethal toxicity observed even at doses 50-100 times typical effective doses. Adverse events in animal studies are minimal. However, human safety data remains extremely limited. In the small number of human users reporting experiences, common side effects are rare and typically mild, including occasional headache (particularly during the first 1-2 weeks), mild fatigue, or transient gastrointestinal upset with oral dosing.

Overdose risk from acute administration is considered low based on preclinical data, but cumulative exposure effects in humans are unknown. Doses exceeding 200 mg daily (oral) or 500 mcg daily (subcutaneous) have not been systematically evaluated and should be avoided. If accidental overdose occurs (e.g., taking twice the intended dose), monitoring for gastrointestinal discomfort or transient headache is appropriate; seek medical evaluation if severe symptoms develop.

Potential long-term concerns relate to chronic NNMT inhibition: permanent upregulation of compensatory methylation pathways, effects on methyl-donor availability (affecting creatine and other methylated compounds), or unexpected impacts on NAD+-dependent signaling. These theoretical risks remain speculative without formal human safety studies. Individuals with pre-existing conditions affecting NAD+ metabolism (e.g., advanced age, certain genetic polymorphisms affecting NAD+ synthesis) should approach 5-Amino-1MQ use with particular caution and medical supervision.

Combining 5-Amino-1MQ with Other Compounds

5-Amino-1MQ's mechanism as an NNMT inhibitor (rather than a growth factor peptide) creates different stacking considerations compared to BPC-157 or TB-500. Combining 5-Amino-1MQ with complementary compounds can amplify metabolic effects, though this increases overall risk and requires careful protocol design.

NAD+ precursors such as NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) theoretically synergize with 5-Amino-1MQ by providing additional substrate for NAD+ synthesis; however, combining high-dose NAD+ boosters with NNMT inhibitors has not been evaluated and could produce excessive NAD+ elevation with unknown consequences. Conservative dosing of NAD+ precursors (500-1000 mg NMN or 250-500 mg NR daily) if combined with 5-Amino-1MQ may be reasonable, but is unvalidated.

Combining 5-Amino-1MQ with peptides like BPC-157 or TB-500 is theoretically compatible, as their mechanisms are distinct (NNMT inhibition versus growth factor signaling). However, this stacking approach increases cumulative injection frequency and unknown interaction risk. Separating injection sites and timing (e.g., 5-Amino-1MQ in the morning, peptides in the evening) is prudent if stacking.

Avoid combining 5-Amino-1MQ with other NNMT inhibitors or NAD+-modulating compounds lacking published safety data in humans. Alcohol consumption during 5-Amino-1MQ cycles should be minimal, as both alcohol and NNMT inhibition stress hepatic NAD+ metabolism and methylation pathways.

Reconstitution, Storage, and Preparation Best Practices

Proper handling of lyophilized 5-Amino-1MQ powder is essential for maintaining potency and ensuring safety. The compound arrives as a freeze-dried powder and must be reconstituted before use. The standard reconstitution vehicle is bacteriostatic sodium chloride (0.9% saline with 0.9% benzyl alcohol as preservative), which maintains sterility and allows extended storage of reconstituted solution. Pharmaceutical-grade bacteriostatic saline should be obtained from legitimate sources (pharmaceutical suppliers, not research chemical vendors selling untested solutions).

Reconstitution volume and concentration should be calculated based on intended dosing frequency. For example, if using 300 mcg daily via subcutaneous injection, reconstituting 50 mg powder with 1 mL of bacteriostatic saline produces a 50 mg/mL solution, allowing precise microdosing with a standard insulin syringe. A 50-mg vial reconstituted this way yields approximately 167 days of daily 300 mcg doses (50 mg × 1,000 mcg/mg ÷ 300 mcg daily), making a single vial sufficient for extended protocols. Alternatively, reconstituting with 2 mL produces 25 mg/mL concentration, requiring 12 units on a 100-unit insulin syringe for a 300 mcg dose, which may be less precise.

Reconstituted 5-Amino-1MQ should be stored in a refrigerator at 2-8°C (35-46°F) in an airtight glass or plastic vial protected from light. Bacterial contamination risk increases if solution is left at room temperature; the benzyl alcohol preservative extends stability to approximately 24-30 days after reconstitution if refrigerated, but longer storage in real-world conditions may reduce potency. Dating the reconstituted vial and discarding after 30 days minimizes risk. Injection sites should be rotated systematically and skin should be cleaned with alcohol wipes before each injection. Using clean (sterile if possible) insulin syringes and needles for each injection is essential; reusing needles increases infection risk.

For oral administration, 5-Amino-1MQ capsules or powder should be stored in a cool, dry location away from direct sunlight. Moisture and heat degrade the compound; storing in a sealed container with desiccant packets extends shelf life. Expiration dates should be observed, as potency degrades over time. Mixing reconstituted powder with food or beverages to improve palatability is sometimes reported but should be done immediately before consumption, as the compound's stability in food is unknown.

Quality Control, Purity, and Sourcing Concerns

A critical but often overlooked aspect of 5-Amino-1MQ use is source quality and purity. Unlike FDA-approved pharmaceuticals, research chemicals are not subject to mandated quality control standards. Compounds purchased from vendors may contain undeclared impurities, incorrect dosages, or inactive products. This creates substantial risk: injecting or ingesting an impure product could expose users to unknown contaminants, rendering efficacy assessments meaningless and creating potential safety hazards.

Evaluating vendor legitimacy is challenging but important. Reputable research chemical suppliers typically provide third-party laboratory analysis (certificates of analysis, COA) documenting purity, identity, and absence of microbial contamination. COA documents should specify HPLC (high-performance liquid chromatography) or similar analytical confirmation of compound identity and purity percentage (target ≥98%). Vendors refusing to provide COA documents should be avoided. Additionally, reputable suppliers are established businesses with professional websites, clear contact information, and histories of consistent product quality; anonymous vendors or those with only cryptocurrency payment options carry higher risk.

Individual users can perform basic quality verification. For subcutaneous injections, reconstituted 5-Amino-1MQ should be colorless to slightly yellow, clear (not cloudy), and free of particulates or precipitation. Visible contamination, cloudiness, or particles suggest degradation, contamination, or incorrect product and should result in product disposal. For oral capsules, consistency of effects across multiple batches suggests stable quality; dramatic variations between purchases from different batches may indicate purity inconsistency or misrepresentation.

Ultimately, use of research chemicals carries inherent risk because formal safety and quality oversight is absent. Users accept this risk when using 5-Amino-1MQ and should factor source legitimacy and quality verification into dosing and outcome interpretation. Compounds from established vendors with documented quality control show better efficacy and safety profiles than those from questionable sources.

Individual Response Variability and Dose Optimization

Optimal 5-Amino-1MQ dosing varies substantially between individuals due to genetic, physiological, and metabolic differences. Understanding this variability helps guide personalized dose optimization rather than assuming standard recommendations apply universally.

Genetic factors influence NNMT expression level and activity. Some individuals naturally express lower NNMT activity due to genetic variations; these individuals may require lower doses for complete NNMT inhibition because the enzyme is less abundant to begin with. Conversely, individuals with naturally higher NNMT expression may require doses toward the higher end of recommended ranges (150 mg oral, 500 mcg subcutaneous) for equivalent enzyme inhibition. While individual NNMT genotyping is not yet routinely available, relative NNMT levels can be estimated indirectly: individuals with chronic metabolic dysfunction (obesity, insulin resistance, poor glucose tolerance) typically express elevated NNMT and may benefit from higher doses, while metabolically healthy individuals may respond to lower doses.

Age-related NAD+ decline affects dose response substantially. Individuals over 50 often demonstrate more dramatic responses to 5-Amino-1MQ at lower doses because their baseline NAD+ is naturally lower, making external NNMT inhibition more impactful. A 60-year-old using 50 mg oral daily might experience effects comparable to a 30-year-old using 100 mg daily, reflecting age-related NAD+ differences. Weight and lean body mass also influence optimal dosing; heavier individuals with substantial lean mass require higher doses (due to larger body size and greater mitochondrial mass consuming NAD+), while lighter individuals typically require proportionally lower doses.

Individual tolerance to side effects varies significantly. Some users experience headaches or GI discomfort at doses others tolerate easily; these individuals should optimize toward the lower end of dosing ranges. Conversely, users showing no side effects at standard doses might experiment cautiously with dose increases to assess whether higher doses produce additional benefit. This personalized titration approach, implemented systematically over weeks, allows identification of individual optimal dose rather than assuming standard recommendations apply universally.

Progress Monitoring and Protocol Assessment During Cycles

Systematic monitoring during a 5-Amino-1MQ cycle provides objective feedback on protocol efficacy and helps identify whether current dosing is optimal or should be adjusted. Several monitoring strategies provide useful data.

Subjective symptom tracking via journal or app is the simplest approach. Daily notation of energy levels (1-10 scale), appetite (reduced/normal/increased), mood, sleep quality, workout performance, and any adverse effects reveals patterns over weeks. Most users report increased energy within days of starting or increasing dose; this early response suggests NNMT inhibition is occurring. Sustained energy elevation through week 4-12 suggests maintained adequate dosing, while energy decline at weeks 8-10 may indicate dose optimization opportunity (increasing dose slightly, as metabolic adaptation is reducing effect) or simply fatigue from extended training and deficit (suggesting cycle conclusion is appropriate).

Biometric measurements provide objective data. Weekly weigh-ins at consistent time (morning after fasting, before food intake) track scale weight change. While scale weight includes water, glycogen, and fat, weekly averages smooth daily noise and reveal trend. Progressive weekly weight loss of 0.5-2 lbs weekly weeks 3-10, then plateau weeks 10-14, is typical. Faster loss (3+ lbs weekly consistently) suggests deficit is too aggressive and may reflect muscle loss rather than pure fat loss. Slower loss (0.1-0.3 lbs weekly) despite apparent adequate deficit suggests either suboptimal dosing or measurement inconsistency. Waist circumference measured at consistent location (1 inch above navel) weekly provides fat-loss specific data. Waist circumference reduction typically tracks fat loss more directly than scale weight (which includes water and other changes).

Workout performance benchmarking provides functional assessment. Re-testing strength benchmarks (e.g., 1-rep max squat, bench press, or deadlift) at cycle start, mid-cycle (week 6), and cycle end reveals training progress. Enhanced strength progression during 5-Amino-1MQ use (compared to training alone) suggests optimal dosing and adequate recovery and nutrition. Stalled strength progression despite training consistency suggests either suboptimal dosing, inadequate nutrition/recovery, or excessive training fatigue, guiding protocol adjustments.

Body composition analysis via DEXA, bioelectrical impedance, or other methods conducted at cycle start and end quantifies fat loss and lean mass preservation. This objective measurement clarifies whether weight loss is primarily fat (desired) or includes substantial muscle loss (suboptimal), informing future protocol decisions. Users unable to access formal body composition testing can estimate via progress photos (monthly photos in standardized lighting and posture, reviewed for visible muscularity and definition changes) and visual assessments of body shape changes complemented by scale and waist measurements.

Symptom escalation assessment—noting whether side effects (headache, fatigue, digestive upset) improve or worsen throughout the cycle—guides dose adjustments. Decreasing side effects as weeks progress suggests adaptation and may permit dose increase. Persistent or worsening side effects despite dose maintenance suggest reducing dose by 25-50% or concluding the cycle early.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions